Introducing the New Weil Institute!

In January of 2022, the family of Dr. Max Harry Weil gifted a donation to Michigan Max Harry Weil Institute for Critical Care Research and Innovation. Since then, the center formerly known as “MICRCC” has grown exponentially, forming new partnerships, launching new events, and supporting bold new research. But for everything new, the mission driving us remains the same: Transforming critical care through innovation, integration & entrepreneurship.

RESEARCH SUPPORT SUCCESS STORIES
This year, Weil Institute Core Teams and special events like our Grand Challenges helped bring in a combined total of $16,316,567 in research funding to our membership.

$5.7 MILLION in NIH funding for development of wearable sensor that detects over 20 diseases and conditions using a patient’s body odor. Led by Dr. Xudong (Sherman) Fan and team from the University of Michigan College of Engineering and Medical School.

$4 + MILLION in DoD follow-on funding to three projects initially supported by the Massey TBI Grand Challenge. Two of the projects are led by Dr. Frederick Korley, who is working in partnership with Dr. Mark Burns. The third is led by Drs. Joseph Wider and Tom Sanderson.

$3.3 MILLION in NICHD funding to research new methods of managing pediatric sepsis led by Dr. Prashant Mahajan alongside a team of investigators from Nationwide Children’s Hospital.

$1.15 MILLION NINDS grant for Dr. Cindy Hsu and Dr. Frederick Korley’s pre-clinical model of brain injury following cardiac arrest.

MARKETING & OUTREACH
1,384 followers on social media
The Marketing Team also overhauled the Weil Institute’s website, including our entire product portfolio, to refine how we position ourselves online.

PROPOSAL DEVELOPMENT TEAM
44% total funding success rate* $15M in grants funded
*Compare to the average NIH/DoD funding success rate of ~20% or less

CLINICAL RESEARCH TEAM
18 studies completed and ongoing
1,487 patients recruited and/or surveyed

LARGE ANIMAL LABORATORY
4 new models developed
- Cardiac Arrest, Resuscitation, and 24-Hour ICU Care
- Impella CP CPR with Balloon Aortic Occlusion
- Blunt Impact Traumatic Brain Injury
- Sepsis Driven Acute Kidney Injury

DATA SCIENCE & DATA OPERATIONS TEAM
$4.3M in sponsorship dollars received in 2022

PRODUCTS & COMMERCIALIZATION
6 new products licensed this year
10 patent applications submitted this year
2 new spin-off companies formed

PARPARTNERSHIPS & COLLABORATIONS
AirStrip, Inc. partnered with Weil Institute Data Science team to license DETECT-ARDS and the PICTURE suite of predictive analytics and integrate them into the existing AirStrip ONE platform.

Weil Institute and Blu Biotech collaborating to develop sepsis/ARDS biomarkers for use with the Micro-GC breath analyzer to enable much earlier detection and treatment of these life-threatening critical illnesses.

Weil Institute and ABIOMED teamed up to study use of Abiomed’s Impella CP® device with aortic occlusion as enhanced strategy for cardiac arrest resuscitation.

MASSEY TBI GRAND CHALLENGE
$1,062,792 in total research funding awarded

Through the generous support of the Joyce and Don Massey Family Foundation, this year marked our very first Million-Dollar Grand Challenge!

KAHN PEDIATRIC CRITICAL CARE PROGRAM
Just launched in December through a gift from philanthropist Mark Kahn to help transform care and outcomes for critically ill children.

SEMINARS & UNIVERSITY EVENTS
Weil Innovation Showcased to U-M Community
The Digital External Ventricular Drain (DEV), developed by Rodney Daniels, MD, was featured at “Celebrate Invention” hosted by Innovation Partnerships in downtown Ann Arbor.

Weil Institute Welcomes Global Scholars
Our 2022 “Visiting Scholar” seminar series gave a warm Michigan welcome to Dr. Lars Larsson, an expert in critical care myopathy from Sweden, and Dr. Renaud Tissier, a physician and professor from France who is leading research into hypothermia in post-cardiac arrest syndrome.

Transforming critical care through innovation, integration & entrepreneurship.